FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SCYNEXIS's Free Cash Flow for the
three
months ended in Dec. 2023 was $-7.7 Mil. SCYNEXIS's Revenue for the
three
months ended in Dec. 2023 was $5.8 Mil. Therefore, SCYNEXIS's FCF Margin % for the quarter that ended in Dec. 2023 was -133.43%.
The historical rank and industry rank for SCYNEXIS's FCF Margin % or its related term are showing as below:
SCYX'
s FCF Margin % Range Over the Past 10 Years
Min: -31503.31 Med: -9555.64 Max: 42.93
Current: 42.93
During the past 12 years, the highest FCF Margin % of SCYNEXIS was 42.93%. The lowest was -31503.31%. And the median was -9555.64%.
SCYX's FCF Margin % is ranked better than 97.66% of 1026
companies
in the Drug Manufacturers industry
Industry Median: -0.68
vs SCYX: 42.93
SCYNEXIS FCF Margin % Historical Data
The historical data trend for SCYNEXIS's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS's FCF Margin % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's FCF Margin % distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's FCF Margin % falls into.
SCYNEXIS FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
SCYNEXIS's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS FCF Margin % Related Terms
Thank you for viewing the detailed overview of SCYNEXIS's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCYX has been successfully added to your 